<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03114683</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI308B201</org_study_id>
    <nct_id>NCT03114683</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma</brief_title>
  <acronym>ORIENT-1</acronym>
  <official_title>Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma: a Multicenter, Single Arm, Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to evaluate ORR, CR, PR DCR DOR PFS and safety of IBI308 in treatment of&#xD;
      patients with Relapsed/Refractory Hodgkin's Lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with classical Hodgkin lymphoma(cHL) who relapse after autologous stem-cell&#xD;
      transplantation(ASCT) or progress after multiple lines of chemotherapy have a poor prognosis,&#xD;
      with a median survival of approximately 1.2 years.&#xD;
&#xD;
      CHL frequently harbors a spectrum of chromosome 9p24.1/PD-L1/PD-L2 alterations, leading to&#xD;
      overexpression of the programmed death 1 ligands,PD-L1 and PD-L2.&#xD;
&#xD;
      Sintilimab is a humanized monoclonal antibody against PD-1 that blocks the interaction&#xD;
      between PD-1 and its ligands and was approved for relapsed/refractory Hodgkin lymphoma in&#xD;
      China in 2018.&#xD;
&#xD;
      This study is a single arm,phase 2 study designed to evaluate the clinical activity of&#xD;
      sintilimab in Chinese patients with R/R&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2017</start_date>
  <completion_date type="Actual">November 30, 2019</completion_date>
  <primary_completion_date type="Actual">September 12, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) Assessed According to the Revised International Working Group Response Criteria for Malignant Lymphoma in 2007(IWG 2007) by the Independent Radiological Review Committee (IRRC).</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Per Revised International Working Group Response Criteria for Malignant Lymphoma in 2007(IWG 2007) assessed by CT and PET: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), ≥50% decrease in SPD of up to 6 largest dominant masses, no increase in size of other nodes; Overall Response (OR) = CR + PR</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Relapsed/Refractory Classical Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>IBI308</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD1</intervention_name>
    <description>IBI308 200mg/3 weeks</description>
    <arm_group_label>IBI308</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histopathological confirmed classical Hodgkin's lymphoma (cHL).&#xD;
&#xD;
          2. Relapsed/refractory cHL, which failed second line and above therapy (including&#xD;
             radiotherapy and autologous hematopoietic stem cell transplantation, ASCT); subject&#xD;
             with no response to or with progression after ASCT is eligible.&#xD;
&#xD;
          3. At least one measurable disease (long axis&gt;15 mm or short axis&gt;10 mm, with uptake on&#xD;
             18FDG-PET)&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2.&#xD;
&#xD;
          5. Signed written informed consent form and willing and able to comply with scheduled&#xD;
             visits and other requirements of the study.&#xD;
&#xD;
          6. Age ≥ 18.&#xD;
&#xD;
          7. Life expectancy of at least 12 weeks.&#xD;
&#xD;
          8. Subjects of reproductive potential must be willing to use adequate contraception&#xD;
             during the course of the study and through 90 days after the last dose of study&#xD;
             medication.&#xD;
&#xD;
          9. Adequate organ and bone marrow function:&#xD;
&#xD;
               1. Count of Blood Cells: absolute neutrophil count (ANC) ≥ 0.75 × 109 / L; platelet&#xD;
                  count (PLT) ≥ 50 × 109 / L; hemoglobin content (HGB) ≥ 8.0 g / dL; no granulocyte&#xD;
                  colony-stimulating factor, platelet or red blood cells infusion in the last 14&#xD;
                  days.&#xD;
&#xD;
               2. Liver function: total bilirubin (TBIL) ≤ 1.5 × normal upper limit (ULN); alanine&#xD;
                  aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN.&#xD;
&#xD;
               3. Renal function: serum creatinine (Cr) ≤ 1.5 × ULN.&#xD;
&#xD;
               4. Thyroid function: thyroid stimulating hormone (TSH) in normal range (TSH&#xD;
                  abnormalities due to non-autoimmune causes can be enrolled).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known nodular lymphocyte predominant Hodgkin lymphoma.&#xD;
&#xD;
          2. Known central nervous system lymphoma.&#xD;
&#xD;
          3. Received ASCT within 90 days of the first dose of study medication.&#xD;
&#xD;
          4. Prior exposure to any anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibody.&#xD;
&#xD;
          5. Currently participating in an interventional clinical study, unless participating in&#xD;
             observational study or during follow-up period of an interventional study.&#xD;
&#xD;
          6. Received any investigational agent within 4 weeks of the first dose of study&#xD;
             medication.&#xD;
&#xD;
          7. Received last dose of radiotherapy or anti-tumor therapy (chemotherapy, targeted&#xD;
             therapy, tumor immunotherapy or arterial embolization) within 3 weeks of the first&#xD;
             dose of study medication; received last dose of nitrosourea or mitomycin C within 6&#xD;
             weeks of the first dose of study medication.&#xD;
&#xD;
          8. Received systemic treatment with corticosteroids (&gt; 10 mg daily prednisone equivalent)&#xD;
             or other immunosuppressive medications within 4 weeks of first dose. Inhaled or&#xD;
             topical steroids and adrenal replacement steroid doses are permitted in the absence of&#xD;
             active autoimmune disease.&#xD;
&#xD;
          9. Received a live vaccine within 4 weeks of the first dose of study medication or plan&#xD;
             to receive live vaccine during study period.&#xD;
&#xD;
         10. Underwent major operation (craniotomy, thoracotomy or laparotomy) within 4 weeks of&#xD;
             the first dose of study medication or open wound, ulcer or fracture.&#xD;
&#xD;
         11. Activated, known or suspected autoimmune diseases or history of the disease with two&#xD;
             years before enrollment. Vitiligo, psoriasis, hair loss, or Graves disease which do&#xD;
             not need systemic treatment in 2 years, or hypothyroidism which only need thyroid&#xD;
             hormone replacement therapy, or type-1 diabetes which only need insulin replacement&#xD;
             therapy is eligible for enrollment.&#xD;
&#xD;
         12. Known primary immunodeficiency disorders.&#xD;
&#xD;
         13. Active tuberculosis.&#xD;
&#xD;
         14. Known history of allogeneic organ or allogeneic hemopoietic stem cell transplantation.&#xD;
&#xD;
         15. Known allergy or hypersensitivity to any monoclonal antibodies or any components used&#xD;
             in their preparation.&#xD;
&#xD;
         16. Uncontrolled concomitant disease, including but not limited to :&#xD;
&#xD;
               1. Human Immunodeficiency Virus (HIV) infection (HIV antibody positive)&#xD;
&#xD;
               2. Active or poorly controlled severe infection&#xD;
&#xD;
               3. Symptomatic congestive heart failure (New York Heart Association grade Ⅲ-IV) or&#xD;
                  symptomatic, poorly controlled arrhythmia&#xD;
&#xD;
               4. Poorly controlled arterial hypertension (SBP ≥ 160mmHg or DBP ≥ 100mmHg) with&#xD;
                  standard treatment&#xD;
&#xD;
               5. Prior arterial thromboembolism event, including myocardial infarction, unstable&#xD;
                  angina, stroke or transient ischemic attack, within 6 months before enrollment&#xD;
&#xD;
               6. Prior life-threatening blood loss or grade 3/4 gastrointestinal/varicosity&#xD;
                  bleeding requiring blood infusion, endoscopic or surgical intervention within 3&#xD;
                  months of enrollment&#xD;
&#xD;
               7. Prior deep vein thrombosis, pulmonary embolism or any other severe&#xD;
                  thromboembolism events (implanted port or catheter caused thrombosis, or&#xD;
                  superficial vein thrombosis are not considered as severe thromboembolism events)&#xD;
                  within 3 months before enrollment&#xD;
&#xD;
               8. History of uncontrolled metabolic disorder, non-malignant organ or systemic&#xD;
                  disease or secondary carcinomatous reaction, with high medical risk and/or&#xD;
                  uncertainty of survival evaluation&#xD;
&#xD;
               9. With hepatic encephalopathy, hepato-renal syndrome or hepatic cirrhosis of&#xD;
                  Child-Pugh grade B or higher.&#xD;
&#xD;
              10. History of intestinal obstruction or the following diseases: inflammatory bowel&#xD;
                  disease or extensive bowel resection (partial colonic resection or extensive&#xD;
                  small bowel resection, concomitant with chronic diarrhea), Crohn's disease,&#xD;
                  ulcerative colitis or chronic diarrhea&#xD;
&#xD;
              11. Other acute or chronic diseases, mental illness, or abnormal laboratory test&#xD;
                  results that may lead to the following outcomes: increase the risk of&#xD;
                  participating in study or study drug administration, or interfere with the&#xD;
                  interpretation of the study results and considered by investigator as &quot;NOT&quot;&#xD;
                  eligible to participate in this study&#xD;
&#xD;
         17. Known acute or chronic active hepatitis B infection (chronic HBV carrier or non-active&#xD;
             HBsAg positive subject is eligible) or acute or chronic active hepatitis C (HCV&#xD;
             antibody negative subject is eligible; HCV RNA examination is required for HCV&#xD;
             antibody positive subject, subject is eligible for enrollment if result was negative)&#xD;
&#xD;
         18. History of gastrointestinal perforation and /or fistula within 6 months before&#xD;
             enrollment&#xD;
&#xD;
         19. Subjects with interstitial lung disease&#xD;
&#xD;
         20. Uncontrolled third space effusion, e.g. ascites or pleural effusion cannot be drained&#xD;
             or controlled&#xD;
&#xD;
         21. Other primary malignancy, with the exception of:&#xD;
&#xD;
               1. Curable malignancy (e.g. papillary thyroid carcinoma)&#xD;
&#xD;
               2. Without active disease in the last 5 years and with very low recurrence risk&#xD;
&#xD;
               3. Non-melanoma skin cancer or malignant freckle-like nevus with adequate treatment&#xD;
                  and no evidence of recurrence ;&#xD;
&#xD;
               4. Adequately treated in-situ carcinoma&#xD;
&#xD;
         22. Women who are pregnant or in lactation period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer hospital Chinese academy of Medical sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/30612710/</url>
    <description>Lancet Haematology 2019;6:e12-19</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/32304999/</url>
    <description>Lancet Haematology 2019;6:e12-19 (full text)</description>
  </link>
  <reference>
    <citation>Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, Zhang W, Gao Y, Jin Z, Zhou J, Jin C, Zou L, Qiu L, Li W, Yang J, Hou M, Zeng S, Zhang Q, Hu J, Zhou H, Xiong Y, Liu P. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2019 Jan;6(1):e12-e19. doi: 10.1016/S2352-3026(18)30192-3.</citation>
    <PMID>30612710</PMID>
  </reference>
  <reference>
    <citation>Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, Zhang W, Gao Y, Jin Z, Zhou J, Jin C, Zou L, Qiu L, Li W, Yang J, Hou M, Xiong Y, Zhou H, Du X, Wang X, Peng B. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab. EBioMedicine. 2020 Apr;54:102731. doi: 10.1016/j.ebiom.2020.102731.</citation>
    <PMID>32304999</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 4, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <results_first_submitted>October 12, 2020</results_first_submitted>
  <results_first_submitted_qc>November 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 7, 2020</results_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hodgkin Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT03114683/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Update analysis data cutoff date of safety data: 30 Sep, 2019. Update analysis data cutoff date of efficacy data: 12 Feb, 2018.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sintilimab</title>
          <description>Subjects received sintilimab 200mg by intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 2 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sintilimab</title>
          <description>Subjects received sintilimab 200mg by intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 2 years</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.83" spread="10.884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (ORR) Assessed According to the Revised International Working Group Response Criteria for Malignant Lymphoma in 2007(IWG 2007) by the Independent Radiological Review Committee (IRRC).</title>
        <description>Per Revised International Working Group Response Criteria for Malignant Lymphoma in 2007(IWG 2007) assessed by CT and PET: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), ≥50% decrease in SPD of up to 6 largest dominant masses, no increase in size of other nodes; Overall Response (OR) = CR + PR</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sintilimab</title>
            <description>Subjects received sintilimab 200mg by intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) Assessed According to the Revised International Working Group Response Criteria for Malignant Lymphoma in 2007(IWG 2007) by the Independent Radiological Review Committee (IRRC).</title>
          <description>Per Revised International Working Group Response Criteria for Malignant Lymphoma in 2007(IWG 2007) assessed by CT and PET: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), ≥50% decrease in SPD of up to 6 largest dominant masses, no increase in size of other nodes; Overall Response (OR) = CR + PR</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4" lower_limit="76.7" upper_limit="91.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Cutoff date of 30 Sep,2019 Serious AEs: Up to 90 days after last administration of investigation products Other AEs: Up to 90 days after last administration of investigation products</time_frame>
      <desc>All adverse events, including serious adverse events, will be collected since the consent form is signed until 90th day after last administration of investigation products, either observed by investigator or by the spontaneous reported by subjects.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sintilimab</title>
          <description>Subjects received sintilimab 200mg by intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 2 years</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Myocardial necrosis marker increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis bullous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Thyroxine free decreased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Bilirubin conjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave abnormal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Lymphocyte percentage decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Tri-iodothyronine decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Tri-iodothyronine free increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yi Bo</name_or_title>
      <organization>Innovent Biologics (Suzhou) Co., Ltd. (seal)</organization>
      <phone>+8613382419112</phone>
      <email>jessica.yi@innoventbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

